Prometheus is developing a mAb for Ulcerative Colitis & Crohn’s Disease

"Merck has agreed to buy Prometheus Biosciences for $10.8bn as the US drugmaker bolsters it pipeline ahead of the possible loss of exclusivity over its best-selling cancer drug later this decade."

https://www.ft.com/content/c92946ef-a240-4a79-a9a5-0028bd252051